Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Flatt
Peter R. Flatt, Co. Antrim GB
| Patent application number | Description | Published |
|---|---|---|
| 20100129934 | Glycated Insulin as a Biomarker for Diagnosis and Monitoring of Diabetes - One of the major pathophysiological consequences of long term elevation of plasma glucose in diabetes is an increase in the non-enzymatic glycation of proteins. Contrary to expectations the present inventors have determined that individuals with well controlled short duration diabetes have particularly high concentrations of glycated insulin which decrease with increased disease severity and duration of diabetes. Further, a small proportion of apparently normal healthy individuals exhibit high glycated insulin levels in line with expected incidence of diabetes in the population. Methods of predicting the onset of diabetes and for monitoring the progression of diabetes by measuring the concentration of Glycated Insulin and the progression of diabetes are disclosed. | 05-27-2010 |
Peter Raymond Flatt, Antrim GB
| Patent application number | Description | Published |
|---|---|---|
| 20090170762 | Treatment of Diabetes Related Obesity - Peptide analogues and uses are provided for treating and preventing obesity and for treating, preventing and reversing weight gain and related metabolic disease, and promoting weight loss and weight maintenance, by administering a medicament comprising an antagonist of GIP receptor, which is a peptide analogue of GIP. | 07-02-2009 |
| 20100227816 | Use of GLP-1 Analogues for the Treatment of Disorders Associated with Dysfunctional Synaptic Transmission - The present invention relates to a peptide analogue of glucagon-like peptide-1 (7-36), which is useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the LTP of synaptic transmission. Moreover, sustaining LTP may find utility in the prophylaxis of neurological disease by delaying the onset of impaired cognitive processes, and could serve as a treatment, not only for the diminished cognitive function caused by neurodegeneration, but also for the dysfunctional cognitive processes associated with trauma or age. | 09-09-2010 |
Peter Raymond Flatt, County Antrim GB
| Patent application number | Description | Published |
|---|---|---|
| 20090286722 | Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function - Peptide analogues and methods are provided for treating age-related symptoms of decreased pancreatic beta-cell function, including glucose intolerance, type 2 diabetes, beta-cell glucose insensitivity, insulin resistance and reduced insulin secretion. | 11-19-2009 |
| 20100204106 | Use of GIP for the Treatment of Disorders Associated with Dysfunctional Synaptic Transmission - The present invention relates to a peptide comprising at least 12 amino acid residues from the N-terminal end of gastric inhibitory polypeptide, or an analogue thereof, which are useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the LTP of synaptic transmission. Moreover, sustaining LTP may find utility in the prophylaxis of neurological disease by delaying the onset of impaired cognitive processes, and could serve as a treatment, not only for the diminished cognitive function caused by neurodegeneration, but also for the dysfunctional cognitive processes associated with trauma or age. Additionally, the peptides and analogues of the present invention find are useful to improve the altered cognitive function associated with hyperexcitability-type disorders, by reducing the elevated level of LTP of synaptic transmission. | 08-12-2010 |
Peter Raymond Flatt, Portrush GB
| Patent application number | Description | Published |
|---|---|---|
| 20090281032 | Modified CCK peptides - The invention concerns a peptide based on biologically active CCK-8. The peptide has improved characteristics for the treatment of at least one of obesity and type 2 diabetes and has the structure: | 11-12-2009 |
| 20100267628 | Analogs of Gastric Inhibitory Polypeptide and Their Use for Treatment of Diabetes - The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes. | 10-21-2010 |
Robert Flatt, Feldmeilen CH
| Patent application number | Description | Published |
|---|---|---|
| 20100018440 | SOLIDIFICATION AND HARDENING ACCELERATOR FOR HYDRAULIC BINDERS AND PROCESS FOR ITS PREPARATION - The present invention relates to a fluoride-free solidification and hardening accelerator for hydraulic binders, comprising sulfate, aluminium and organic acid, the molar ratio of aluminium to sulfate being less than 0.83. | 01-28-2010 |
Robert Flatt, Zurich CH
| Patent application number | Description | Published |
|---|---|---|
| 20090205427 | Device and Method for Determining the Dynamic Elastic Modulus of a Material - The invention relates to the determination of the dynamic elastic modulus of a material, such as a material comprising a mineral binder like cement, or gypsum, or the like, or a polymer, or ceramic, preferably mortar or concrete, in particular shotcrete, using sound, preferably ultrasound waves which penetrate the material and are continuously measured and analyzed. In particular, the invention relates to an apparatus, to a measuring device, and to a method for determining the dynamic elastic modulus of a material using the apparatus. | 08-20-2009 |
Robert Flatt, Kitchener CA
| Patent application number | Description | Published |
|---|---|---|
| 20110216205 | AUTOMATIC CALIBRATION OF PROJECTION SYSTEM USING NON-VISIBLE LIGHT - A method and apparatus for calibration of a projection system, comprising projecting visible and non-visible images on at least one image plane, detecting said non-visible images projected on the image plane, and calibrating projection of the visible images using the non-visible images. The visible and non-visible images are simultaneously projected and the non-visible images are continually monitored for automatic calibration of composite displays, without taking the projection system off-line. In addition, calibration can be maintained through continuous automatic adjustment using invisible calibration patterns, even if the system is disturbed while it is operating. | 09-08-2011 |